331 related articles for article (PubMed ID: 24063277)
1. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.
Brents LK; Prather PL
Drug Metab Rev; 2014 Feb; 46(1):72-85. PubMed ID: 24063277
[TBL] [Abstract][Full Text] [Related]
2. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
[TBL] [Abstract][Full Text] [Related]
3. Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.
Brents LK; Zimmerman SM; Saffell AR; Prather PL; Fantegrossi WE
J Pharmacol Exp Ther; 2013 Sep; 346(3):350-61. PubMed ID: 23801678
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Cannabinoids.
Mills B; Yepes A; Nugent K
Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018.
Su MK; Seely KA; Moran JH; Hoffman RS
Clin Pharmacol Ther; 2015 Jun; 97(6):562-4. PubMed ID: 25788107
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.
Sholler DJ; Huestis MA; Amendolara B; Vandrey R; Cooper ZD
Pharmacol Biochem Behav; 2020 Dec; 199():173059. PubMed ID: 33086126
[TBL] [Abstract][Full Text] [Related]
7. Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain.
Samano KL; Poklis JL; Lichtman AH; Poklis A
J Anal Toxicol; 2014; 38(6):307-14. PubMed ID: 24816398
[TBL] [Abstract][Full Text] [Related]
8. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.
Brents LK; Gallus-Zawada A; Radominska-Pandya A; Vasiljevik T; Prisinzano TE; Fantegrossi WE; Moran JH; Prather PL
Biochem Pharmacol; 2012 Apr; 83(7):952-61. PubMed ID: 22266354
[TBL] [Abstract][Full Text] [Related]
9. Spicing things up: synthetic cannabinoids.
Spaderna M; Addy PH; D'Souza DC
Psychopharmacology (Berl); 2013 Aug; 228(4):525-40. PubMed ID: 23836028
[TBL] [Abstract][Full Text] [Related]
10. Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice.
Wilson CD; Tai S; Ewing L; Crane J; Lockhart T; Fujiwara R; Radominska-Pandya A; Fantegrossi WE
J Pharmacol Exp Ther; 2019 Feb; 368(2):146-156. PubMed ID: 30420360
[TBL] [Abstract][Full Text] [Related]
11. Synthetic cannabinoid JWH-018 and psychosis: an explorative study.
Every-Palmer S
Drug Alcohol Depend; 2011 Sep; 117(2-3):152-7. PubMed ID: 21316162
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds.
Dresen S; Ferreirós N; Pütz M; Westphal F; Zimmermann R; Auwärter V
J Mass Spectrom; 2010 Oct; 45(10):1186-94. PubMed ID: 20857386
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Pot: Not Your Grandfather's Marijuana.
Ford BM; Tai S; Fantegrossi WE; Prather PL
Trends Pharmacol Sci; 2017 Mar; 38(3):257-276. PubMed ID: 28162792
[TBL] [Abstract][Full Text] [Related]
14. Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events.
Davidson C; Opacka-Juffry J; Arevalo-Martin A; Garcia-Ovejero D; Molina-Holgado E; Molina-Holgado F
Adv Pharmacol; 2017; 80():135-168. PubMed ID: 28826533
[TBL] [Abstract][Full Text] [Related]
15. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.
Seely KA; Lapoint J; Moran JH; Fattore L
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):234-43. PubMed ID: 22561602
[TBL] [Abstract][Full Text] [Related]
16. A survey study to characterize use of Spice products (synthetic cannabinoids).
Vandrey R; Dunn KE; Fry JA; Girling ER
Drug Alcohol Depend; 2012 Jan; 120(1-3):238-41. PubMed ID: 21835562
[TBL] [Abstract][Full Text] [Related]
17. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?
Seely KA; Prather PL; James LP; Moran JH
Mol Interv; 2011 Feb; 11(1):36-51. PubMed ID: 21441120
[TBL] [Abstract][Full Text] [Related]
18. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants.
Patton AL; Seely KA; Yarbrough AL; Fantegrossi W; James LP; McCain KR; Fujiwara R; Prather PL; Moran JH; Radominska-Pandya A
Biochem Biophys Res Commun; 2018 Apr; 498(3):597-602. PubMed ID: 29522717
[TBL] [Abstract][Full Text] [Related]
19. Using Web searches to track interest in synthetic cannabinoids (a/k/a 'herbal incense').
Curtis B; Alanis-Hirsch K; Kaynak Ö; Cacciola J; Meyers K; McLellan AT
Drug Alcohol Rev; 2015 Jan; 34(1):105-8. PubMed ID: 25196534
[TBL] [Abstract][Full Text] [Related]
20. The Synthetic Cannabinoids Phenomenon.
Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
